1 Contact Hour(s)
Rush University Medical Center
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.
After completing this program, participants should be able to:
- Formulate individualized, evidence-based treatment plans for multiple myeloma patients in the VHA, DoD and MHS settings, by applying current standards of care and appropriately sequencing new agents and combinations while considering expert recommendations, disease and patient characteristics and patient needs/preferences
- Evaluate the latest clinical trial data including the evolution of new classes of therapeutics and how to safely and effectively integrate them into care across the disease spectrum of multiple myeloma
- Describe the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.
Joshua Richter, MD
Mount Sinai Hospital
New York, NY